Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KANDLELIT-013 adjuvant MK-1084 plus MK-3475A versus placebo plus MK-3475A in resected KRAS G12C-mutant non-small cell lung cancer
2024-517337-41-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of calderasib and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Disease-Free Survival. Planned start May 2026; status: authorised.
02
Drugs
calderasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-517337-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517337-41-00.